keyword
MENU ▼
Read by QxMD icon Read
search

Dydrogesterone

keyword
https://www.readbyqxmd.com/read/29778368/oral-dydrogesterone-for-luteal-phase-support-in-fresh-in-vitro-fertilization-cycles-a-new-standard
#1
REVIEW
Georg Griesinger, Christophe Blockeel, Herman Tournaye
Oral dydrogesterone has been used for luteal phase support on an empirical basis since the early days of in vitro fertilization (IVF) treatment. Systematic comparisons of oral dydrogesterone with vaginal progesterone, so far considered to be the standard of care, started to appear in the middle 2000s. Recently, a large, randomized, double-blind, double-dummy phase III trial on the use of daily 30 mg oral dydrogesterone versus daily 600 mg micronized vaginal progesterone for LPS in IVF was published. This company-sponsored trial confirmed the efficacy findings from previous independent researchers and firmly established the noninferiority of daily 30 mg oral dydrogesterone for luteal phase support...
May 2018: Fertility and Sterility
https://www.readbyqxmd.com/read/29747269/-effect-of-low-dose-or-standard-dose-conjugated-equine-estrogen-combined-with-different-progesterone-on-bone-density-in-menopause-syndrome-women
#2
H L Zuo, Y Deng, Y F Wang, L L Gao, W Xue, S Y Zhu, X Ma, A J Sun
Objective: To explore the effect of low-dose or standard-dose conjugated equine estrogen (CEE) combined with natural progesterone or dydrogesterone on bone density in menopause syndrome women. Methods: Totally 123 patients with menopause syndrome were recruited and randomly assigned to 3 treatment groups: group A (low-dose CEE+progesterone) , group B (standard-dose CEE+progesterone) , group C (standard-dose CEE+dydrogesterone) . Using continuous sequential regimen, the duration of intervention was 12 cycles...
April 25, 2018: Zhonghua Fu Chan Ke za Zhi
https://www.readbyqxmd.com/read/29508649/new-data-about-preeclampsia-some-possibilities-of-prevention
#3
Adolf E Schindler
This concise report deals with the known effects of progestogen lack in early pregnancy with failure of implantation and blood supply to the placenta depending on proper trophoblast invasion, spiral artery remodeling, and vessel dilatation. The pathophysiology of preeclampsia will be outlined and the most recent data on the effect of dydrogesterone presented. Dydrogesterone appears to be able to reduce significantly the development of preeclampsia. The effect is related to begin with such prevention and this should be continued until 37th weeks of gestation which would also mean prevention of premature labor...
March 6, 2018: Gynecological Endocrinology
https://www.readbyqxmd.com/read/29488367/oral-dydrogesterone-vs-vaginal-progesterone-capsules-for-luteal-phase-support-in-women-undergoing-embryo-transfer-a-systematic-review-and-meta-analysis
#4
Marina Wanderley Paes Barbosa, Natália Paes Barbosa Valadares, Antônio César Paes Barbosa, Adelino Silva Amaral, José Rubens Iglesias, Carolina Oliveira Nastri, Wellington de Paula Martins, Hitomi Miura Nakagawa
OBJECTIVE: To identify, appraise, and summarize the evidence from randomized controlled trials (RCTs) comparing oral dydrogesterone to vaginal progesterone capsules for luteal-phase support (LPS) in women offered fresh or frozen embryo transfers following in vitro fertilization. METHODS: Two independent authors screened the literature for papers based on titles and abstracts, then selected the studies, extracted data, and assessed the risk of bias. Dydrogesterone and progesterone were compared based on risk ratios (RR) and the precision of the estimates was assessed through the 95% confidence interval (CI)...
February 28, 2018: JBRA Assisted Reproduction
https://www.readbyqxmd.com/read/29317960/different-effects-of-oral-contraceptive-and-dydrogesterone-treatment-on-oxidative-stress-levels-in-premenopausal-women
#5
Jui-Tung Chen, Kazuhiko Kotani
Background: The aim of the study was to observe the changes in blood oxidative stress levels by oral contraceptive (OC) and/or dydrogesterone (DG) treatment. Methods: A retrospective cohort of 27 premenopausal women with primary dysmenorrhea consisted of the OC treatment group (N = 17) and the DG treatment group (N = 10) by choice of the initial treatment. The OC group included two subgroups: patients with continuous OC treatment (treated for at least 15 months, N = 10) and patients with discontinuous OC treatment (switched to DG treatment after approximately 6 months of initial OC treatment: N = 7)...
February 2018: Journal of Clinical Medicine Research
https://www.readbyqxmd.com/read/29300975/new-application-of-dydrogesterone-as-a-part-of-a-progestin-primed-ovarian-stimulation-protocol-for-ivf-a-randomized-controlled-trial-including-516-first-ivf-icsi-cycles
#6
Sha Yu, Hui Long, Hannah Ya-Ning Chang, Yali Liu, Hongyuan Gao, Jing Zhu, Xinxin Quan, Qifeng Lyu, Yanping Kuang, Ai Ai
STUDY QUESTION: Can dydrogesterone (DYG) be used as an alternative progestin in a progesterone primed ovarian stimulation (PPOS) protocol? SUMMARY ANSWER: DYG can be used as an appropriate alternative progestin in a PPOS protocol. WHAT IS KNOWN ALREADY: PPOS is a new ovarian stimulation regimen based on a freeze-all strategy that uses progestin as an alternative to a GnRH analog for suppressing a premature LH surge during the follicular phase...
February 1, 2018: Human Reproduction
https://www.readbyqxmd.com/read/29136850/novel-generation-of-deep-eutectic-solvent-as-an-acceptor-phase-in-three-phase-hollow-fiber-liquid-phase-microextraction-for-extraction-and-preconcentration-of-steroidal-hormones-from-biological-fluids
#7
Mohammad Mahdi Khataei, Yadollah Yamini, Ali Nazaripour, Meghdad Karimi
In this study, a novel generation of deep eutectic solvents (DESs) was used as an acceptor phase in three-phase hollow fiber liquid phase microextraction (HF-LPME) based on two immiscible organic phases. It was compared with other common DESs for extraction and preconcentration of dydrogesterone (DYD) and cyproterone acetate (CPA) from urine and plasma samples. The extracted analytes were analyzed by high performance liquid chromatography with UV-vis detector (HPLC-UV). This phosphonium based DES due to low volatility, low price and multifunctionality introduced itself as worthy next generation of acceptor phase in HF-LPME...
February 1, 2018: Talanta
https://www.readbyqxmd.com/read/28981954/differential-effect-of-the-ultra-low-dose-and-standard-estrogen-plus-dydrogesterone-therapy-on-thrombin-generation-and-fibrinolysis-in-postmenopausal-women
#8
Magdalena Piróg, Robert Jach, Olga Kacalska-Janssen
INTRODUCTION: The objective of this study was to estimate the effects of different doses of oral hormone therapy (HT) on thrombin generation and fibrinolytic activity in postmenopausal women after 12 months of treatment. MATERIAL AND METHODS: Thrombin generation, fibrinolysis activators and inhibitors were determined before and after 12 months of treatment. Participants (180) were assigned (1:1:1) as follows: (1) standard HT group, 17β-estradiol (1 mg/day) with dydrogesterone (5 mg/day); (2) ultra-low dose HT group, 17β-estradiol (0...
December 2017: Acta Obstetricia et Gynecologica Scandinavica
https://www.readbyqxmd.com/read/28938733/a-phase-iii-randomized-controlled-trial-comparing-the-efficacy-safety-and-tolerability-of-oral-dydrogesterone-versus-micronized-vaginal-progesterone-for-luteal-support-in-in-vitro-fertilization
#9
Herman Tournaye, Gennady T Sukhikh, Elke Kahler, Georg Griesinger
No abstract text is available yet for this article.
October 1, 2017: Human Reproduction
https://www.readbyqxmd.com/read/28865249/effects-of-ultra-low-dose-versus-standard-hormone-therapy-on-fibrinolysis-and-thrombin-generation-in-postmenopausal-women
#10
Magdalena Piróg, Robert Jach, Anetta Undas
OBJECTIVE: To assess the effects of different doses of oral hormone therapy (HT) on thrombin generation and fibrinolysis. STUDY DESIGN: One hundred fifty postmenopausal women were assigned in a randomized controlled study in which the effect of standard dose (1mg 17β-estradiol/5mg dydrogesterone), ultra-low-dose HT (0.5mg 17β-estradiol/2.5mg dydrogesterone) on fibrinolysis and coagulation was compared to controls. Factors measured included plasma clot lysis time (CLT), fibrinolysis activators and inhibitors, thrombin generation (prothrombin fragments 1+2 [F1+2], endogenous thrombin potential [ETP]), normalized activated protein C sensitivity ratio (nAPCsr), and factor (F)VIII activity and were determined before and after 24 weeks of HT...
October 2017: European Journal of Obstetrics, Gynecology, and Reproductive Biology
https://www.readbyqxmd.com/read/28609128/the-effect-of-different-progestogens-on-sleep-in-postmenopausal-women-a-randomized-trial
#11
Ekachai Leeangkoonsathian, Tawiwan Pantasri, Somsak Chaovisitseree, Nuntana Morakot
BACKGROUND: While progesterone affects sleep, different types of it might affect sleep differently. METHODS: One hundred Thai women, who complained of insomnia, visited the Menopause Clinic at Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand from February 2014 to March 2015, and were divided randomly into two groups. Both groups received daily hormonal treatment that included estradiol valerate (progynova) at 1 mg. The first group also received dydrogesterone (duphaston® ) at 10 mg and the second group micronized progesterone (utrogestran® ) at 100 mg...
December 2017: Gynecological Endocrinology
https://www.readbyqxmd.com/read/28502186/effectiveness-of-dydrogesterone-17-oh-progesterone-and-micronized-progesterone-in-prevention-of-preterm-birth-in-women-with-a-short-cervix
#12
Olga Pustotina
OBJECTIVE: To compare the efficacy of dydrogesterone, 17-OH progesterone (17OHP) and oral or vaginal micronized progesterone with cerclage for the prevention of preterm birth in women with a short cervix. METHODS: The study included 95 women with singleton gestation and cervical length (CL) ≤ 25 mm. Among these, 35 women were asymptomatic at 15-24 weeks and 60 had symptoms of threatened late miscarriage (LM) or preterm delivery (PD) at 15-32 weeks. Patients were randomized to receive dydrogesterone, 17OHP or oral/vaginal micronized progesterone; after one week of therapy 15 women underwent cerclage...
July 2018: Journal of Maternal-fetal & Neonatal Medicine
https://www.readbyqxmd.com/read/28435101/interaction-of-glucocorticoids-and-progesterone-derivatives-with-human-serum-albumin
#13
Rola Abboud, Mohammad Akil, Catherine Charcosset, Hélène Greige-Gerges
Glucocorticoids (GCs) and progesterone derivatives (PGDs) are steroid hormones with well-known biological activities. Their interaction with human serum albumin (HSA) may control their distribution. Their binding to albumin is poorly studied in literature. This paper deals with the interaction of a series of GCs (cortisol, cortisone, prednisolone, prednisone, 6-methylprednisolone and 9-fluorocortisol acetate) and PGDs (progesterone, hydroxylated PGDs, methylated PGDs and dydrogesterone) with HSA solution (pH 7...
October 2017: Chemistry and Physics of Lipids
https://www.readbyqxmd.com/read/28333318/a-phase-iii-randomized-controlled-trial-comparing-the-efficacy-safety-and-tolerability-of-oral-dydrogesterone-versus-micronized-vaginal-progesterone-for-luteal-support-in-in-vitro-fertilization
#14
RANDOMIZED CONTROLLED TRIAL
Herman Tournaye, Gennady T Sukhikh, Elke Kahler, Georg Griesinger
STUDY QUESTION: Is oral dydrogesterone 30 mg daily (10 mg three times daily [TID]) non-inferior to micronized vaginal progesterone (MVP) 600 mg daily (200 mg TID) for luteal support in in vitro fertilization (IVF), assessed by the presence of fetal heartbeats determined by transvaginal ultrasound at 12 weeks of gestation? SUMMARY ANSWER: Non-inferiority of oral dydrogesterone versus MVP was demonstrated at 12 weeks of gestation, with a difference in pregnancy rate and an associated confidence interval (CI) that were both within the non-inferiority margin...
May 1, 2017: Human Reproduction
https://www.readbyqxmd.com/read/28317410/sex-hormone-binding-globulin-and-antithrombin-iii-activity-in-women-with-oral-ultra-low-dose-estradiol
#15
COMPARATIVE STUDY
Sumika Matsui, Toshiyuki Yasui, Kana Kasai, Kaoru Keyama, Kanako Yoshida, Takeshi Kato, Hirokazu Uemura, Akira Kuwahara, Toshiya Matsuzaki, Minoru Irahara
Oral oestrogen increases the risk of venous thromboembolism (VTE) and increases production of sex hormone-binding globulin (SHBG) in a dose-dependent manner. SHBG has been suggested to be involved in venous thromboembolism. We examined the effects of oral ultra-low-dose oestradiol on circulating levels of SHBG and coagulation parameters, and we compared the effects to those of transdermal oestradiol. Twenty women received oral oestradiol (500 μg) every day (oral ultra-low-dose group) and 20 women received a transdermal patch (50 μg) as a transdermal group...
July 2017: Journal of Obstetrics and Gynaecology: the Journal of the Institute of Obstetrics and Gynaecology
https://www.readbyqxmd.com/read/28214940/transcriptional-and-biochemical-alterations-in-zebrafish-eleuthero-embryos-danio-rerio-after-exposure-to-synthetic-progestogen-dydrogesterone
#16
Wen-Jun Shi, Guang-Guo Ying, Guo-Yong Huang, Yan-Qiu Liang, Li-Xin Hu, Jian-Liang Zhao, Jin-Na Zhang
Little information has so far been known on the effects of synthetic progestogen dydrogesterone (DDG) in organisms like fish. This study aimed to investigate the effects of DDG on the transcriptional and biochemical alterations in zebrafish eleuthero-embryos. Zebrafish eleuthero-embryos were analyzed for the transcriptional alterations by real-time quantitative PCR (RT-qPCR) and biochemical changes by attenuated total reflection Fourier-transform infrared spectroscopy (ATR-FITR) after 144 h exposure to DDG...
July 2017: Bulletin of Environmental Contamination and Toxicology
https://www.readbyqxmd.com/read/27973242/economic-assessment-of-dydrogesterone-compared-with-progesterone-for-the-treatment-of-threatened-andhabitual-miscarriage-in-china
#17
M Connolly, Q Tian, M Sierra, L Zhang, V Vaskantiras
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27900987/effect-of-half-dose-and-standard-dose-conjugated-equine-estrogens-combined-with-natural-progesterone-or-dydrogesterone-on-components-of-metabolic-syndrome-in-healthy-postmenopausal-women-a-randomized-controlled-trial
#18
RANDOMIZED CONTROLLED TRIAL
Wei Xue, Yan Deng, Yan-Fang Wang, Ai-Jun Sun
BACKGROUND: Menopausal hormone therapy (MHT) has been proven to have beneficial effects on several components of metabolic syndrome. However, the effects vary according to different regimens, dosages, and duration of MHT. The aim of the study was to evaluate the effect of standard-dose 0.625 mg conjugated equine estrogen (CEE) and half-dose 0.3 mg CEE daily with different progestogens in a continuous sequential regimen on postmenopausal metabolic parameters in generally healthy postmenopausal women...
December 5, 2016: Chinese Medical Journal
https://www.readbyqxmd.com/read/27898258/estradiol-therapy-and-breast-cancer-risk-in-perimenopausal-and-postmenopausal-women-a-systematic-review-and-meta-analysis
#19
REVIEW
Zhilan Yang, Ying Hu, Jing Zhang, Liangzhi Xu, Rujun Zeng, Deying Kang
OBJECTIVE: To investigate the association between estradiol therapy and incidence of breast cancer, taking into consideration of different types of combined progestogen, the duration of exposure and the type of regimen. METHOD: A systematic review and meta-analysis. RESULT: A total of 14 studies were included in our study. In estradiol-only therapy analysis, meta-analysis resulted a pooled OR =0.90, 95% CI (0.40, 2.02) from the RCTs and pooled OR = 1...
February 2017: Gynecological Endocrinology
https://www.readbyqxmd.com/read/27887710/supplementation-with-progestogens-in-the-first-trimester-of-pregnancy-to-prevent-miscarriage-in-women-with-unexplained-recurrent-miscarriage-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials
#20
REVIEW
Gabriele Saccone, Corina Schoen, Jason M Franasiak, Richard T Scott, Vincenzo Berghella
OBJECTIVE: To investigate whether treatment with progestogens in the first trimester of pregnancy would decrease the incidence of miscarriage in women with a history of unexplained recurrent miscarriage. DESIGN: Systematic review and meta-analysis. SETTING: Not applicable. PATIENT(S): Women with a history of unexplained recurrent miscarriage. INTERVENTION(S): Randomized, controlled trials were identified by searching electronic databases...
February 2017: Fertility and Sterility
keyword
keyword
94180
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"